China Reforms Welcome, But More Needed: Frazier
This article was originally published in PharmAsia News
Visiting Beijing on another grey day choked with thick smog, PhRMA chairman Kenneth Frazier stressed the need for drug companies to adopt flexible pricing practices in the Chinese market, along with reimbursement and other measures to support innovation, and a globally-harmonized, science-based, transparent and predictable regulatory framework.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.